Revance Continues To Expect 2024 Total Net Product Revenue, Which Includes Sales Of DAXXIFY And RHA Collection, To Be At Least $280M
With cash, cash equivalents, and short-term investments of $277.1 million as of March 31, 2024, and anticipated revenues and expenditures, management projects that the company will be funded to cash flow break-even and reach positive Adjusted EBITDA in 2025.